Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

NCT03575234 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped funding and drug were withdrawn

Conditions

Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions

DRUG: Cyclophosphamide
BIOLOGICAL: IRX-2
BIOLOGICAL: Nivolumab
PROCEDURE: Surgery

Sponsor

Emory University

Collaborators

[object Object]
[object Object]